AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
AbbVie Inc will acquire Apogee Therapeutics for $135.11 per share in cash, valuing the transaction at approximately $10.9 billion, adding clinical-stage therapies for inflammatory and immunological diseases to its pipeline.
AbbVie Inc (NYSE:) will acquire Apogee Therapeutics (NASDAQ:) for $135.11 per share in cash, valuing the all-cash transaction at approximately $10.9 billion, the companies announced Sunday under a definitive agreement.
The deal adds a pipeline of clinical-stage therapies for inflammatory and immunological diseases to AbbVie's portfolio, including programs targeting atopic dermatitis and asthma. AbbVie will acquire all outstanding Apogee shares at the stated per-share price.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.